A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors.
Status:
Not yet recruiting
Trial end date:
2025-01-16
Target enrollment:
Participant gender:
Summary
A multicenter, open-label, phase I dose escalation study to evaluate the safety,
tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination
with YH001 in subjects with advanced solid tumors